RBC Capital Maintains Outperform on Chemours, Raises Price Target to $15

Benzinga · 07/03 14:40
RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $14 to $15.